CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
At the recent annual meeting of the Austrian Working Group for Gynaecological Oncology in the Austrian Society for Gynecology and Obstetrics the Ernst Wertheim Award was presented to Dr Marie Plante, the CCTG CX5 study lead and Gynecologic Oncologist at CHU de Quebec, Canada.
The CCTG Annual Spring Meeting is only 4 weeks away
All meeting information is available on the Spring Meeting Web Page and includes:
Meeting Invitation - Important deadlines
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative volunteer for the Breast Disease Site Committee.
CCTG has been working closely with our NCI/CTSU counterparts to develop the process and workflow for investigator and research staff registrations. Here is what is understood as we move toward implementation:
1. All individuals that are registered at the time of the changeover will be grandfathered.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative volunteer for the Investigational New Drug (IND) Committee.
CCTG is excited to extend our congratulations to Dr. Lillian Siu who was recently announced as the 2024 ASCO David Karnofsky Memorial Award winner. The award and lecture are presented during the upcoming ASCO Annual Meeting in honor of outstanding contributions to the research, in the diagnosis and treatment of cancer.
Please join CCTG on April 10 from 11:00 to 12:00 pm EST for a virtual round table on strategies for improving equity and access in cancer clinical trials. We are honoured to bring together Dr. Don S. Dizon and Dr. Sara Moore to guide us in this conversation which will be moderated by Dr. Janet Dancey. The goal of this discussion is to help participants consider strategies for enhancing clinical trial diversity and making clinical trials more accessible to all populations that may benefit from them.
